Utibron Neohaler (indacaterol/glycopyrrolate), which is expected to be available in the first quarter of next year, can be used for the long-term maintenance treatment of airflow obstruction in
The biopharmaceutical firm expects to enroll patients later this year. ProMetic is currently undertaking a phase II clinical trial of PBI-4050 in Canada in patients with metabolic syndrome
The Institute of Cancer Research (ICR), London, carried out the study on Olaparib drug with the Royal Marsden NHS Foundation Trust and other funding bodies. The drug was
Yervoy, a monoclonal antibody that blocks CTLA-4 (cytotoxic T-lymphocyte antigen), is used to treat patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of over 1
The recall affects all Auvi-Q products on the US market and includes both the 0.15 mg and 0.3 mg strengths. It includes lots number 2299596 through 3037230 with
UCSF associate professor in the department of surgery Qizhi Tang is undertaking a research on a novel transplantation immunotherapy that is expected to minimize rates of organ rejection
The companies will assess the potential of antibody-drug conjugates (ADCs) targeting Surface Antigen in Leukemia (SAIL). SAIL is a novel cell surface protein with high prevalence of expression
The company said a review of data from a phase III trial of losmapimod for heart treatment did not indicate efficacy against the primary endpoint. Losmapimod was being
Trek Therapeutics recently secured an exclusive worldwide license from Theravance Biopharma to develop, manufacture, use, market and sell TD-6450 as a component in combination HCV products. Under the
The study, funded by the Medical Research Council and Alzheimer’s Society, involved 295 people who had been diagnosed with moderate to severe Alzheimer’s disease. The main objective of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.